Order Article Reprints

Alosaimi B, Alshanbari HM, Alturaiqy M, AlRawi HZ, Alamri S, Albujaidy A, Bin Sabaan A, Alrashed AA, Alamer A, Alghofaili F, et al. Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir. Pharmaceuticals. 2022; 15(12):1456. https://doi.org/10.3390/ph15121456

Alosaimi, Bandar, Huda M. Alshanbari, Muath Alturaiqy, Halah Z. AlRawi, Saad Alamri, Asma Albujaidy, Aljawharah Bin Sabaan, Ahmed A. Alrashed, Ahmad Alamer, Fayez Alghofaili, and et al. 2022. "Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir" Pharmaceuticals 15, no. 12: 1456. https://doi.org/10.3390/ph15121456

Alosaimi, B., Alshanbari, H. M., Alturaiqy, M., AlRawi, H. Z., Alamri, S., Albujaidy, A., Bin Sabaan, A., Alrashed, A. A., Alamer, A., Alghofaili, F., Al-Duraymih, K., Alshalani, A. J., & Alturaiki, W. (2022). Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir. Pharmaceuticals, 15(12), 1456. https://doi.org/10.3390/ph15121456